Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation
- 1 April 2000
- Vol. 55 (4) , 521-525
- https://doi.org/10.1016/s0090-4295(99)00538-5
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma.Journal of Clinical Oncology, 1998
- A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urotheliumCancer, 1996
- Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissuesHuman Pathology, 1996
- Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosisNature Medicine, 1996
- Paclitaxel, Cisplatin and Methotrexate Combination Chemotherapy is Active in the Treatment of Refractory Urothelial MalignanciesJournal of Urology, 1995
- A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.Journal of Clinical Oncology, 1992
- M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Transitional Cell Carcinoma of the UrotheliumJournal of Urology, 1988
- Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.Journal of Clinical Oncology, 1985
- The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agentJournal of Chronic Diseases, 1961